Editing Openai/69101fc6-f990-800a-9638-7716259af6c4 (section)

=== (“multi” with ubiquinol (CoQ10), probiotic L. acidophilus, flavonoids like fisetin/luteolin, B-vitamins, iodine, etc.) ===
* Plasma CoQ10 ↑; Endothelial function (FMD) ↑ ~1.5 % absolute on average Measure: plasma CoQ10; FMD at vascular lab Why: CoQ10 supports mitochondrial electron transport and endothelial NO bioavailability. PubMed<ref>{{cite web|title=PubMed|url=https://pubmed.ncbi.nlm.nih.gov/38630421/|publisher=pubmed.ncbi.nlm.nih.gov|access-date=2025-11-09}}</ref>MDPI<ref>{{cite web|title=MDPI|url=https://www.mdpi.com/2072-6643/12/4/1098|publisher=mdpi.com|access-date=2025-11-09}}</ref>
* LDL-C ↓ small amounts with Lactobacillus probiotics in dyslipidemic/overweight populations (e.g., ~0.1–0.3 mmol/L ≈ 4–12 mg/dL) over 8–12 weeks; effects are strain-dependent and variable in healthy people Measure: lipid panel; optional ApoB Why: bile-acid deconjugation, SCFA production, and cholesterol assimilation in the gut. PMC<ref>{{cite web|title=PMC|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC5805418/|publisher=pmc.ncbi.nlm.nih.gov|access-date=2025-11-09}}</ref>ScienceDirect<ref>{{cite web|title=ScienceDirect|url=https://www.sciencedirect.com/science/article/pii/S1756464621003601|publisher=sciencedirect.com|access-date=2025-11-09}}</ref>NMCD Journal<ref>{{cite web|title=NMCD Journal|url=https://www.nmcd-journal.com/article/S0939-4753%2819%2930382-5/fulltext|publisher=NMCD Journal|access-date=2025-11-09}}</ref>
* Homocysteine ↓ if your folate/B12 were low (via methylated folate/Bs) Measure: plasma homocysteine Why: improved one-carbon metabolism; lower homocysteine is cardio-protective surrogate (general consensus; no single source cited).
* NAD+: if the capsule set includes nicotinamide riboside (NR) (often taken separately), expect blood/PBMC NAD+ ↑ ~60–140% in 6–8 weeks; cardiometabolic markers usually unchanged in healthy adults Measure: PBMC or dried blood spot NAD+ (specialty labs) Why: NR fuels NAD+ pools for redox and sirtuin/PARP activity. Nature<ref>{{cite web|title=Nature|url=https://www.nature.com/articles/s41467-018-03421-7|publisher=nature.com|access-date=2025-11-09}}</ref>PMC<ref>{{cite web|title=PMC|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC10828186/|publisher=pmc.ncbi.nlm.nih.gov|access-date=2025-11-09}}</ref>
* Fisetin/luteolin: human RCT evidence for hard biomarkers over 90 d in healthy adults is limited; ongoing trials target inflammation/senescence in specific conditions. PMC<ref>{{cite web|title=PMC|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC11492760/|publisher=pmc.ncbi.nlm.nih.gov|access-date=2025-11-09}}</ref>